Kenji Hashimoto
Chief Medical Officer United Immunity
Dr. Kenji Hashimoto is a board-certified medical oncologist with over 20 years of experience across academia and industry. He has been a CMO for a few biotech companies and most recently he was tenure CMO at Crescendo Biologics, supporting the transition from preclinical to clinical development of a T-cell engager. He has been in pharma industry over 10 years mainly in cell therapies and immuno-therapies, Kenji holds a PhD in Medical Oncology from the University of Oxford and a medical degree from Gunma University, Japan.
Seminars
Tuesday 9th February 2027
Harnessing CAR-Macrophages to Overcome Solid Tumour Barriers In Vivo
11:30 am
- Exploring CAR-Macrophages as an alternative cell platform to overcome the limitations of CAR-T therapies in solid tumours
- Leveraging innate immune functions to penetrate the tumour microenvironment, enhance tumour infiltration, and drive durable responses
- Demonstrating the preclinical potential of in vivo cell therapy approaches to enhance accessibility for solid tumours
